Please join us at the 9th Annual Fluidigm Mass Cytometry Virtual Summit
The successful use of CyTOF® technology for mass cytometry has resulted in its application in over 100 clinical research trials and a bibliography fast approaching 1,000 peer-reviewed publications. Today researchers around the world are routinely performing phenotypic and functional studies in cell suspensions using mass cytometry as well as in tissues using Imaging Mass Cytometry™ (IMC™) to explore the complexity of the single-cell tissue microenvironment.
The annual Mass Cytometry Summit is an international meeting of the mass cytometry community responsible for all of this amazing research. This event is designed for both new and experienced users, as well as those simply interested in learning more about CyTOF technology and its use in high parameter cytometry (suspension mass cytometry) and IMC.
This year’s program will feature keynotes from leading researchers applying mass cytometry to two very topical areas of investigation: infectious disease and the tumor microenvironment.
In addition, there will be plenary sessions covering multiple applications, special-topic breakout sessions, tutorials to help you advance your own research and plenty of time to network virtually with colleagues and experts in the field.
We’re looking forward to the opportunity that a virtual event offers to extend participation in the Summit this year!
Please join us.
For Research Use Only. Not for use in diagnostic procedures.
Originally from the Midwest, Rebecca Ihrie completed undergraduate studies in biochemistry with honors at the University of Michigan, a PhD in cancer biology at Stanford University and a postdoctoral fellowship in the Alvarez-Buylla lab at the University of California, San Francisco. Her work has been recognized by Stanford’s Lieberman award, the Damon Runyon Cancer Research Foundation, the American Association for Cancer Research/National Brain Tumor Society and an Ann Faulkenberry research grant from the Southeastern Brain Tumor Foundation.
Since 2012, the Ihrie Lab at Vanderbilt University has studied the stem cells of the brain and stem-like cells in brain tumors using high-dimensional approaches. Using flow cytometry, her group revealed intrinsic differences in per-cell signaling capacity between groups of neural stem cells and showed that this difference is linked to the ability of these cells to form brain tumors. The laboratory also demonstrated that brain tumor contact with the brain stem cell niche is a key independent predictor of patient outcome.
Recently the Ihrie Lab and collaborators used mass cytometry analysis of glioblastoma patient tissue and new machine learning algorithms to identify and deeply characterize novel, risk-stratifying populations of brain tumor cells.
Ihrie is a founding member of Vanderbilt’s Mass Cytometry Center of Excellence and a member of the Vanderbilt Brain Institute, the Vanderbilt Center for Stem Cell Biology and the Vanderbilt-Ingram Cancer Center. When not in the lab, she might be roller-skating skating with her family or outside in the garden.
Marcelo Sztein is Professor of Pediatrics, Medicine and Microbiology and Immunology at the University of Maryland, Baltimore (UMB). He is Associate Director for Basic and Translational Research, Leader of the Immunology Group, and Chief of the Cellular Immunology Section at the prestigious Center for Vaccine Development and Global Health (CVD). Sztein is also Director of the Flow Cytometry and Mass Cytometry Core Facility at UMB.
An accomplished investigator in the area of immunology of infectious diseases, Sztein has published over 230 papers in peer-reviewed journals and written 35 invited chapters. In 2002 he established the Immunology Group at the CVD to centralize and expand interdisciplinary efforts in translational research with the ultimate goal of accelerating vaccine development. Over the past three decades he has directly mentored over 25 postdoctoral fellows, medical fellows, graduate students and visiting scientists from the US and overseas. Moreover, he has extensive experience in managing large multidisciplinary teams of investigators as part of NIH contracts and U19 grants and has served as Senior Immunologist and other leadership positions in Vaccine Testing Evaluation Units (VTEU) sponsored studies since 1990.
Sztein’s research focuses on understanding the mechanisms underlying the generation of the innate and adaptive immune responses to infectious organisms and vaccines in humans and animal models and host-pathogen interactions. He has studied children, young adults and the elderly following exposure to wild-type organisms and/or immunization against, among others, Salmonella typhi, Shigella, enterotoxigenic E. coli, V. cholerae, hepatitis B, P. falciparum, influenza, F. tularensis and Ebola. Sztein is an expert in flow cytometry, having been involved in this field since 1984 and having directed flow cytometry core facilities for almost 30 years. Sztein was one of the early adopters of the mass cytometry technology.
Don earned his BS from UCLA in Microbiology, Immunology, and Molecular Genetics and has more than 5 years of experience working in R&D with Dako/Agilent in the field of companion diagnostics. He is experienced in feasibility of Class III medical device development, deployment of clinical trial assays to CROs, and the development of manual scoring algorithms. Don now works in the field of digital pathology and image analysis to combine his work experience and his passion for computers and technology.
El-ad David Amir is Chief Executive Officer and co-founder of Astrolabe Diagnostics, Inc. He has over a decade of experience in computational biology, systems biology and data science in both academic and industry settings. Amir is an expert in the exploration of novel datasets, especially high-dimensional, single-event data, and in making machine learning and statistical analysis accessible to biologists and other colleagues.
Akhila Balachander manages the core Imaging Platform at Singapore Immunology Network (SIgN), Singapore. She graduated from Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany in 2010 and joined SIgN as a post-doctoral fellow in 2012. During a short stint working on dendritic cells, she started managing the microscopy platform in 2013. Akhila has spearheaded and developed several Immunohistochemistry-based technology pipelines and imaging modalities. She is currently involved in setting up the newly acquired Imaging Mass Cytometry™ technology at SIgN.
Rafet Basar received his MD degree in Turkey in 2009 and completed his residency in internal medicine at the Istanbul Faculty of Medicine in 2015. Following his clinical training, he began research training as a postdoctoral research fellow in Stem Cell Transplantation and Cellular Therapy Department in the Division of Cancer Medicine under the mentorship of Katayoun Rezvani, MD, PhD, to focus on adoptive cellular therapy and cancer immunology. Throughout his postdoctoral career at MD Anderson Cancer Center, his work has been dedicated to developing innovative methods to enhance the potency of NK cellular therapy products using state-of-the-art genetic engineering strategies for the treatment of hematologic malignancies. He has also focused on engineering cytotoxic T cells to treat post-transplant viral infections and characterizing B cells for the purpose of viable expansion and suppression along with their role in the tumor milieu. Basar has developed a novel strategy combining chimeric antigen receptor (CAR) engineering with CRISPR Cas9 multiplex gene editing to knock out multiple inhibitory molecules such as TGFBRII, CISH and NKG2A simultaneously in order to generate highly potent cells for cancer immunotherapy.
Bernd Bodenmiller is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor growth for the benefit of patients. He is the founding director of the University of Zurich Department of Quantitative Biomedicine (DQBM), which fosters research and education at the interface of biomedical research, biotechnology and computational biology to guide development of next-generation precision medicine. Bodenmiller obtained his PhD in the Ruedi Aebersold group at ETH Zurich. For his postdoctoral training, he joined the laboratory of Garry P. Nolan at Stanford University. In 2012, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zurich. In 2019, he was tenured and became the founding director of the DQBM. His group pioneered the development of Imaging Mass Cytometry, an approach that enables simultaneously imaging of over 50 proteins and transcripts in tissues (Nature Methods, 2014; Cell Systems, 2017) and the histoCAT™ software toolbox (Nature Methods, 2017). His groups applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting (Nature Biotechnology, 2017; Cell, 2017; Cell, 2019).
Gerd Haga Bringeland graduated from the Faculty of Medicine at the University of Bergen in 2012. She has worked as a resident doctor at the Department of Neurology, Haukeland University Hospital, since 2014. In 2017 she started a PhD project at the Neurological Research Laboratory and the Flow Cytometry Core Facility at the University of Bergen with Sonia Gavasso as main supervisor. They employed mass cytometry to study peripheral leukocytes from multiple sclerosis patients receiving immunotherapy with natalizumab. They developed a method for accurate measurement of receptor occupancy with mass cytometry and studied the clinical relevance of this biomarker in the context of individualized dosing in natalizumab therapy. Bringeland recently defended her thesis, “A mass cytometry receptor occupancy study of natalizumab therapy in multiple sclerosis.” She is currently working as a clinician at the Department of Neurology and is affiliated with the newly established Neuro-SysMed, Norway’s first research center for clinical therapy in neurology.
Sean Burke received his MS degree in biology from New York University. At NYU he utilized flow cytometry to study interactions between multiple HIV-1 viruses within single cells and acted as operator of the College of Dentistry Flow Cytometry Core facility. Prior to NYU he worked at Memorial Sloan Kettering Cancer Center developing methods for automated microscopic analysis of tissue sections at the single-cell level. Over the years he has acquired vast experience with image analysis and flow cytometry methods and has enjoyed the last 10 years at De Novo Software™ helping researchers and scientists around the world advance data analysis techniques using FCS Express™.
Jared Burks received his doctoral degree at Texas A&M University, sparking his passion for imaging when he focused on protein trafficking during viral infection. His efforts resulted in the identification of a nuclear pore complex lateral channel shuttle protein (importinα-16). Burks continued to research protein trafficking during his post-doctoral training at Baylor College of Medicine, where he learned to effectively collaborate. In turn, these collaborations honed technical problem-solving skills that made him perfectly suited to direct a state-of-the-art shared resource facility at MD Anderson Cancer Center, where he is an Associate Professor. He has introduced and established multiple technologies including live-cell confocal, multispectral imaging, high-plex imaging and mass cytometry (suspension and imaging). His focus is on understanding how cellular interactions result and drive the spatial distributions of cells. Burks’ technical training allows him to identify, utilize and adapt emerging technologies to answer critical questions in cutting-edge research.
Tim Bushnell has been involved in flow cytometry since his post-doctoral research studying murine B cell development. He started running core facilities in 2003, becoming the director of the University of Rochester Medical Center flow cytometry core in 2008. There he grew the facility, including acquiring a CyTOF® in 2012. He was promoted to the position of Director of the URMC Shared Resource Laboratories in 2012. Bushnell is also active in flow cytometry education, having delivered lectures and training courses in the US and Europe since 2008.
Pei-Yu Chen is a Research Scientist at Yale Cardiovascular Research Center, under the guidance of Professor Michael Simons. Chen’s research centers on the novel mechanisms of vascular dysfunction, with emphasis on clinical relevance and translational research. She applies multidisciplinary integrative analysis, combining mouse disease models with artificial intelligence bioinformatics and human clinical samples. She also uses primary cell culture systems for functional and mechanism studies. Her current research focuses on understanding how transforming growth factor beta (TGF) signaling controls vascular cell fate. She has made a significant contribution to understanding the paradoxical role of TGF signaling and inflammation in vascular disease. She provided the first evidence that endothelial-cell-to-mesenchymal transition (EndMT) contributes to human diseases including transplant rejection and atherosclerosis. This laid the foundation for a series of studies that examined the role of EndMT in cardiovascular biology, with publications in Cell Reports, Science Signaling, The Journal of Clinical Investigation (JCI), EMBO Molecular Medicine and Nature Metabolism, among others. She has also demonstrated the role of cell fate transition in the development of aneurysms. Chen received her BS from Kaohsiung Medical University. She received her PhD in molecular genetics and cell biology from University of Maine.
Matt Cochran began working in the field of flow cytometry in 2004, and he began managing flow cytometry operations shortly thereafter. In 2012 he became the Technical Director of the University of Rochester Medical Center Flow Cytometry Resource (URMC FCR), overseeing day-to-day operations and the training and education program for the FCR. He leads a team of six full-time staff handling 14 instruments. Cochran has also been an active part of the international flow cytometry community as a member of the ISAC Shared Resource Laboratory Content Task Force, the GLIIFCA steering committee and the ABRF Flow Cytometry Research Group.
Kara L. Davis, is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford University, where she is the Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases. She received her BA from Pennsylvania State University and Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine. She completed her pediatrics training at Thomas Jefferson University in Philadelphia, Pennsylvania, and Oncology/Hematology Fellowship at Stanford.
Davis’ research focuses on applying single-cell, high-parameter technologies to the study of childhood cancers to identify cell populations and their features predictive of adverse clinical outcomes. Davis and colleagues have developed a developmental classifier for analysis of B cell acute lymphoblastic leukemia (ALL), and with this tool they uncovered a cell population of leukemic pre-B cells present at diagnosis. This population is highly predictive of future relapse in children. Davis’ group is using these tools to investigate the impact of standard drug treatment or novel immunotherapies on these resistant cells and determining how they are resistant. Using high-dimensional imaging techniques, the group is investigating childhood solid tumors to examine tumor cell heterogeneity and the immune microenvironment.
Davis has also been instrumental in leading clinical trials utilizing the immune system to treat relapsed leukemia and solid tumors. Davis was the institutional PI for the pivotal trial that led to FDA approval of the first cellular therapy for cancer, chimeric antigen T cells. She is a co-investigator on the Stanford bispecific CAR and CD22 CAR trials for relapsed or refractory leukemia and the GD2 CAR for childhood diffuse intrinsic pontine glioma trial. Davis leads the effort in correlative biology studies for these clinical trials. She also co-leads the Children’s Oncology Group (COG) study ADVL1412 studying the role of checkpoint inhibition in pediatric cancer. Clinically, Davis cares for children with newly diagnosed and relapsed acute leukemia with a focus on children receiving CAR therapies.
Melissa B. Davis is an Assistant Professor (Interim) in the Department of Surgery and Scientific Director of the International Center for the Study of Breast Cancer Subtypes (ICSBCS) at Weill Cornell Medical College in New York. She holds adjunct faculty appointments in the Department of Genetics at the University of Georgia in Athens, Georgia, and the Department of Public Health Sciences at Henry Ford Health System in Detroit, Michigan. Davis received her PhD in molecular genetics at the University of Georgia, and her postdoctoral training was completed at Yale School of Medicine and the University of Chicago, where she completed groundbreaking genomics work related to steroid hormone functions during development. She also trained at the University of Chicago Center for Interdisciplinary Health Disparities, where she began her current research program: To identify biological mechanisms of racial disparities in cancer risk and clinical outcomes of cancer diagnoses. The Davis Lab has produced findings proving that unique genetic signatures in both breast and prostate tumors of African and African American patients are enriched for mechanisms that correlate with aggressive tumor progression. Her findings generate novel opportunities for precision medicine applications in minority populations.
Shelley Herbrich is a postdoctoral fellow at the University of Texas MD Anderson Cancer Center in Houston, Texas. She holds a BS in applied mathematics from Texas A&M University and an MS in biostatistics from Johns Hopkins Bloomberg School of Public Health. Herbrich began her career as a bioinformatician before returning to school to pursue a PhD in cancer biology at the University of Texas MD Anderson Graduate School of Biomedical Sciences, where she worked in the Marina Konopleva Lab. Her doctoral work focused on using big data and single-cell techniques to identify novel immunotherapeutic targets in acute myeloid leukemia.
Beth Hill earned a PhD in molecular immunology and biochemistry from the University of Maine and continued research into inflammation/autoimmunity and lymphocyte development as a postdoc at both the University of Maine and the Maine Medical Research Institute. She has over 20 years of experience in flow cytometry and research methods and analysis. Beth joined Verity Software House as an application specialist over eight years ago and has enjoyed providing customers with solutions for their high-dimensional data analyses.
Greg Hopkins is Senior Associate Scientist II in the Analytical Development group at bluebird bio, a biotechnology company based mainly in Cambridge, MA. At bluebird, he oversees day-to-day CyTOF® operations and is involved in many mass cytometry projects that aim to identify clinically correlative characteristics in CAR T cells as well as in stem cell therapeutics. He has been involved in mass cytometry on a nearly daily basis since 2016.
Hopkins received his education from the University of New England in Biddeford, Maine. Prior to bluebird, he held positions at Dana-Farber Cancer Institute, Boston Children’s Hospital and Duke University. He currently lives in the Boston metro area with his family and is enjoying the reduced Boston area traffic since most people started working from home (silver linings …).
Amir Horowitz’s laboratory at the Precision Immunology Institute and Tisch Cancer Institute has contributed to developing an understanding of adaptive NK cells and their roles in cancers, microbial infections and following vaccination and hematopoietic cell transplantation (HCT). Horowitz was the first person to demonstrate adaptive roles for NK cells in vaccine settings as a strategy to enhance T cell memory. This work has since been adapted to study the helper roles of NK cells within tumor microenvironments that facilitate infiltration of cytotoxic T cells. He also pioneered the first studies of human NK cells by mass cytometry (using CyTOF technology) and demonstrated an enormous breadth of phenotypic diversity and functions associated with specific HLA class I and KIR backgrounds. This research has led to the identification and characterization of numerous NK cell and CD8 T cell subset populations with unique activity and antitumor (and antiviral) potential.
Chris Linthwaite has been Chief Executive Officer of Fluidigm since October, 2016. Linthwaite has significant leadership experience across a broad range of life science businesses, including genomics tools, bioprocessing, forensics, ag-bio and animal health testing. Prior to joining Fluidigm, Linthwaite served as President of the Genetic Sciences Division at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. Linthwaite has extensive experience building successful franchises in both life science research markets and a range of regulated environments. He has spearheaded numerous acquisitions and transformed business performance to drive growth. Earlier in his career he was in management consulting at two firms that are now part of PwC, and he co-founded a biomedical organization focused on early-stage technology commercialization. He served on the board of directors of pediatric genetic testing company Claritas Genomics. As an armor officer in the American military, Linthwaite was stationed in Europe and served with distinction as part of the NATO-led Implementation Force conducting peacekeeping operations in Bosnia and Herzegovina. He earned an MBA from the Darden School of Business at the University of Virginia as well as a BA in foreign affairs from UVA. Linthwaite served as a White House intern in the Office of Public Liaison and competed at the varsity level with the UVA wrestling team.
Trevor McKee, the senior data scientist at the STTARR preclinical imaging facility within University Health Network in Toronto, has been developing novel techniques for the acquisition and analysis of microscopy and medical image data for 20 years since earning a PhD at MIT. For the past 10 years McKee has led the computational pathology efforts at the STTARR Core facility to developed new workflows for high-throughput semi-automated analysis in order to perform tissue cytometry, extracting quantitative spatial as well as biomarker information from tissue sections. He has expertise in performing multimodality correlations of information from medical imaging and preclinical radiology with several tissue-based optical and mass spectrometric techniques, including Imaging Mass Cytometry™, with which he has been developing analytical methods for the past five years. He has published 40-plus publications utilizing these analysis pipelines, and he works at the forefront of the application of advanced technologies and integration with pathologist workflows to help extract single-cell proteomic insights and quantitative data from pathological slides and 3D images.
Akil Merchant is an NIH funded physician-scientist who focuses on developing new treatments for cancer by targeting the tumor immune microenvironment. He did his undergraduate studies at Rice University followed by medical school and residency at Baylor College of Medicine. He then completed a fellowship in medical oncology at Johns Hopkins University and was a faculty member at the Keck School of Medicine at the University of Southern California from 2012 to 2018 before joining Cedars-Sinai. The current focus of his lab at Cedars-Sinai is to understand how the tumor immune microenvironment promotes cancer growth and resistance to therapy. A major challenge in studying the tumor microenvironment is the lack of robust technologies that allow for detailed characterization of immune cells while preserving the tissue architecture and spatial relationships between cancer and immune cells. To overcome these obstacles the Merchant Lab has pioneered the application of Imaging Mass Cytometry™ (IMC™) to study the tumor and immune microenvironments in cancer. Merchant is the founding director of a newly established mass cytometry research core at Cedars-Sinai, where other investigators are allowed access to Imaging Mass Cytometry for their research.
Michelle Poulin received her PhD in immunology from the University of Colorado Health Sciences Center. After completing her postdoctoral fellowship at National Jewish Health hospital in Denver, she worked in the customer education department of BD™ Biosciences for almost 10 years. Poulin has supported CyTOF technology as a Field Applications Scientist for DVS Sciences and Fluidigm since 2012. She has managed the North American mass cytometry and Imaging Mass Cytometry Field Applications team since 2015.
Andrew Quong joined the Fluidigm executive team as Chief Science Officer in June, 2019. Previously he was Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute. Frederick National Laboratory is at the forefront of basic, translational and clinical science with a focus on cancer, AIDS and infectious disease. Before joining the Frederick National Laboratory, Quong served as a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University.
Hiranmayi Ravichandran joined Englander Institute of Precision Medicine (EIPM) as a mass cytometry specialist in 2018. She leads the mass cytometry initiative at Weill Cornell Medical College, New York. The acquisition of CyTOF® technology at EIPM was made possible through a generous donation from Mr. Igor Tulchinsky, Founder, Chairman and CEO WorldQuant, LLC, and the WorldQuant Initiative for Quantitative Prediction. As part of EIPM Director Olivier Elemento’s lab, Ravichandran develops and deploys high-dimensional imaging methods using Imaging Mass Cytometry to elucidate the spatial proteomics basis of human disease and physiology. Ongoing research includes single-cell level characterization of the tumor-immune microenvironment of lymphomas, prostate cancer, colorectal cancer and triple-negative breast cancer. She worked as a flow cytometrist at Massachusetts General Hospital Flow Cytometry Core Facility in Boston for three years, where she was also trained on novel CyTOF technology. Her contributions to the field are reflected through publications in journals such as Science and Cell. She completed her MS in pharmacology at Northeastern University.
Emily Thrash leads an immunophenotyping cytometry group in the Center for Immuno-Oncology Immune Assessment Lab (CIO-IAL) at Dana-Farber Cancer Institute. She received her doctorate in biomedical sciences from The Ohio State University College of Medicine. Her expertise in immuno-oncology and translational research has made significant impact on patient care and has led to multiple publications in cytometry methodology and clinical trial reports. In the CIO-IAL, Emily specializes in developing and implementing harmonized CyTOF protocols for clinical trial projects with large sample sizes (>200). Her team has optimized custom mass cytometry panels and novel workflows for multiple cancer and tissue types to allow for high-throughput acquisition with superior robustness and reproducibility.
Handan Xiang is a senior scientist in discovery oncology/immunology at Merck Research Laboratories. She was a post-doctoral fellow in the same institution, where she leveraged cutting-edge techniques to delineate immunosuppressive functions of cancer-associated fibroblasts. Prior to joining Merck, she completed her PhD in the Department of Pharmacology and Cancer Biology at Duke University.
Qianjun Zhang obtained her master's degree in immunology from the University of Colorado, Denver. She has over 10 years of experience in the field of cytometry with a special focus on high-dimensional cytometry data analysis. She is now a Staff Application Scientist at Beckman Coulter Life Sciences. She is also an emeritus ISAC Marylou Ingram Scholar and former ISAC Council member.
At Fluidigm, we empower our customers to reveal meaningful insights in health and disease, identify actionable markers to inform life decisions and accelerate the development of more effective therapies. Fluidigm develops, manufactures, and markets research products for life science analytical and preparatory systems for use in mass cytometry, high-throughput genomics, and single cell genomics applications. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide.